“Fragile X Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Fragile X Syndrome Market.
The Fragile X Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Fragile X Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Fragile X Syndrome and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Fragile X Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Fragile X Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Infusion
-
Intradermal
-
Intramuscular
-
Intranasal
-
Intravenous
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Gene therapies
-
Small molecule
-
Vaccines
-
Polymers
-
Peptides
-
Monoclonal antibodies
Learn How the Ongoing Clinical & Commercial Activities will Affect the Fragile X Syndrome Therapeutic Segment @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight
Fragile X Syndrome Therapeutics Landscape
There are approx. 20+ key companies developing therapies for Fragile X Syndrome. Currently, Zynerba Pharmaceuticals is leading the therapeutic market with its Fragile X Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Players in the Fragile X Syndrome Therapeutics Market Include:
-
Actinogen
-
Alcobra Ltd.
-
Autifony Therapeutics
-
Confluence Pharmaceuticals
-
Healx
-
Hoffmann-La Roche
-
Lysogene
-
Marinus Pharmaceuticals
-
Neuren Pharmaceuticals
-
Nova Mentis
-
Novartis Pharmaceuticals
-
Prilenia Therapeutics
-
Seaside Therapeutics, Inc.
-
Sentinel Oncology
-
Tetra Therapeutics
-
Zynerba Pharmaceuticals
And Many Others
Fragile X Syndrome Therapies Covered in the Report Include:
-
Zatolmilast: Tetra Discovery Partners
-
Zygel: Zynerba Pharmaceuticals
-
Pridopidine: Prilenia Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late Stage Products (Phase-III)
7. Fragile X Syndrome Mid-Stage Products (Phase-II)
8. Fragile X Syndrome Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Key Companies in the Fragile X Syndrome Market
15. Key Products in the Fragile X Syndrome Therapeutics Segment
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Drug Hypersensitivity Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Drug Hypersensitivity market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Drug Hypersensitivity market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/